PMID- 17923756
OWN - NLM
STAT- MEDLINE
DCOM- 20080122
LR  - 20211020
IS  - 1011-8934 (Print)
IS  - 1598-6357 (Electronic)
IS  - 1011-8934 (Linking)
VI  - 22 Suppl
IP  - Suppl
DP  - 2007 Sep
TI  - Combinational treatment with retinoic acid derivatives in non-small cell lung 
      carcinoma in vitro.
PG  - S52-60
AB  - The growth inhibitory effects of four retinoic acid (RA) derivatives, 9-cis RA, 
      13-cis RA, N-(4-hydroxyphenyl) retinamide (4-HPR), and all-trans retinoic acid 
      (ATRA) were compared. In addition, the effects of various combinations of these 
      four agents were examined on non-small cell lung carcinoma (NSCLC) cell-lines, 
      and on the expressions of retinoic acid receptors (RARs) and retinoid X receptors 
      (RXRs) on these cells. At the clinically achievable concentration of 1 microM, 
      only 4-HPR inhibited the growths of H1299 and H460 cells-lines. However, retinoic 
      acid receptor beta(RAR beta) expression was up-regulated on H460 and H1299 cells 
      treated with 1 microM of ATRA, 13-cis RA, or 9-cis RA. All NSCLC cell lines 
      showed growth inhibition when exposed sequentially to 1 microM ATRA and 0.1 
      microM 4-HPR. In particular, sequential treatment with 1 microM ATRA or 13-cis RA 
      and 4-HPR markedly inhibited H1703 cell growth; these cells exhibited no basal 
      RAR beta expression and were refractory to 4-HPR. However, in NSCLC cell lines 
      that expressed RAR beta, the expressional levels of RAR beta were up-regulated by 
      ATRA alone and by sequential treatment with ATRA and 4-HPR. 4-HPR was found to be 
      the most active of the four agents in terms of NSCLC growth-inhibition. Moreover, 
      sequential treatments with ATRA or 13-cis RA followed by 4-HPR were found to have 
      synergistic growth-inhibitory effects and to regulate RAR expression.
FAU - Choi, Eun Jung
AU  - Choi EJ
AD  - Department of Internal Medicine and Brain Korea 21 Program for Biomedical 
      Sciences, Korea University College of Medicine, Seoul, Korea.
FAU - Whang, Young Mi
AU  - Whang YM
FAU - Kim, Seok Jin
AU  - Kim SJ
FAU - Kim, Hyun Jin
AU  - Kim HJ
FAU - Kim, Yeul Hong
AU  - Kim YH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - J Korean Med Sci
JT  - Journal of Korean medical science
JID - 8703518
RN  - 0 (DNA Primers)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoid X Receptors)
RN  - 0 (retinoic acid receptor beta)
RN  - 187EJ7QEXL (Fenretinide)
RN  - 1UA8E65KDZ (Alitretinoin)
RN  - 5688UTC01R (Tretinoin)
RN  - EH28UP18IF (Isotretinoin)
SB  - IM
MH  - Alitretinoin
MH  - Base Sequence
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/metabolism
MH  - Cell Line, Tumor
MH  - DNA Primers/genetics
MH  - Drug Therapy, Combination
MH  - Fenretinide/administration & dosage
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Isotretinoin/administration & dosage
MH  - Lung Neoplasms/*drug therapy/genetics/metabolism
MH  - Receptors, Retinoic Acid/genetics
MH  - Retinoid X Receptors/genetics
MH  - Tretinoin/administration & dosage/*analogs & derivatives
PMC - PMC2694387
EDAT- 2007/12/06 09:00
MHDA- 2008/01/23 09:00
PMCR- 2007/09/01
CRDT- 2007/12/06 09:00
PHST- 2007/12/06 09:00 [pubmed]
PHST- 2008/01/23 09:00 [medline]
PHST- 2007/12/06 09:00 [entrez]
PHST- 2007/09/01 00:00 [pmc-release]
AID - 200709s052 [pii]
AID - 10.3346/jkms.2007.22.S.S52 [doi]
PST - ppublish
SO  - J Korean Med Sci. 2007 Sep;22 Suppl(Suppl):S52-60. doi: 
      10.3346/jkms.2007.22.S.S52.